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Epilepsy is a disease of complex nature and of different etiology (1). A large number
of populations of different age groups and sex are affected by this disease. Mainly, two
kinds of epilepsy have been identified, one with grand mal and the other with petit mal.
Anticonvulsant drugs with MES (maximal electroshock) activity are generally useful in
grand mal, while ScMet (subcutaneous metrazole) antagonists are effective in petit mal.
Many drugs have been marketed recently for the treatment of epilepsy (2–4). These in-
clude milecemide, zonisamide, lamotrigine, felbamate and tiagabine. Recently, semicar-
bazones are emerging as novel anticonvulsant drugs. 4-Bromobenzaldeyde semicarba-
zone and 4-bromophenyl semicarbazones have shown promising activities (5–9). The
proposed pharmacophoric requirements in the semicarbazone molecules are:
(i) aryl binding site with a hydrophobic group;
(ii) hydrogen bonding domain exemplified by the presence of the -NHCO- grouping;
(iii) two electron donor system;
(iv) hydrophobic binding site whose size determines the type of activity.
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Schiff bases of N-methyl and N-acetyl isatin derivatives
with different aryl amines have been synthesized and
screened for anticonvulsant activities against maximal
electroshock (MES) and subcutaneous metrazole (ScMet).
N-methyl-5-bromo-3-(p-chlorophenylimino) isatin (2) ex-
hibited anticonvulsant activity in MES and ScMet with
LD50 > 600 mg kg–1, showing better activity than the stan-
dard drugs phenytoin, carbamazepine and valproic acid.
Thus, compound 2 may be chosen as a prototype for de-
velopment of new anticonvulsants.
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The objective of the present work was to test this hypothesis and as a result, a new
series of compounds have been prepared by reacting N-methyl or N-acetyl isatins with
different aryl amines (Scheme 1):
(i) Isatin has been selected because during initial screening it has shown activity in the
MES test (10–14). In the isatin molecule, bromo substituent has been selected because
of its high potency. Further, an electron withdrawing group, such as NO2, has also
been included for SAR studies (15).
(ii) Schiff bases of aromatic amines have been prepared because they contain a two elec-
tron donor system.
(iii) The N-methyl and N-acetyl groups have been incorporated to increase the lipophili-
city of the molecules.
EXPERIMENTAL
The melting point of the compounds was measured in an open capillary and was
uncorrected. The purity of the compounds was confirmed by thin layer chromatography
using silica gel glass plates as the stationary phase and benzene and ethanol (9:1) as the
mobile phase. IR spectra were recorded on a JASCO FT/IR-5300 spectrophotometer, Ja-
pan. NMR spectra were run on a JEOL FT-NMR spectrometer FX-90Q (Japan) with TMS
as internal reference. Isatin derivatives were prepared by the literature methods (16).
They were characterized by melting point, elemental analysis and spectral data.
The aryl amines were procured from Aldrich (USA) and were used as received.
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Synthesis of Schiff bases. General procedure
Equimolar quantities of 5-substituted N-methyl/N-acetyl isatin (0.003 mol) and aro-
matic amine (0.003 mol) were added into 20 mL of absolute ethanol containing a few
drops of glacial acetic acid in a 250-mL round bottom flask. The reaction mixture was
refluxed for half an hour and then checked for completion by TLC. The solvent was
stripped off and the product was recrystallized from ethanol (99.5%) and characterized
by elemental analysis, IR and 1H NMR.
The physical and spectral data of the synthesized compounds are listed in Tables I
and II, respectively.
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a Mobile phase: benzene/ethanol 9:1
Table I. Continued
Table II. Spectral data of isatin Schiff bases
Compd.
No.
IR (KBr), (cm–1) 1H-NMR (, ppm)
1 3349, 1700, 1702, 1268, 1050, 846, 600
2.8 (s, 3H, N-CH3), 3.73 (s, 3H, OCH3),
6.3–7.7 (m, 7H, Ar-H), 8.4 (s, 1H, CH=N)
2 3450, 1672, 1603, 821, 708, 504
2.8 (s, 3H, N-CH3), 6.3–7.0 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
3 3364, 1750, 1613, 1470, 1294, 845, 577
2.8 (s, 3H, N-CH3), 6.3–7.9 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
4 3383, 3000, 1749, 1701, 1610, 844, 609
2.8 (s, 3H, N-CH3), 6.3–7.9 (m, 7H, Ar-H),
11.0 (s, 1H, COOH), 8.4 (s, 1H, CH=N)
5 3451, 1673, 1605, 1388, 823, 506
2.8 (s, 3H, N-CH3), 6.3–6.7 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
6 3349, 1700, 1702, 1268, 1050, 846, 600
2.4 (s, 3H, COCH3), 3.7 (s, 3H, OCH3),
6.3–8.0 (m, 7H, Ar-H), 8.4 (s, 1H, CH=N)
7 3252, 1687, 1672, 1603, 821, 708, 503
2.4 (s, 3H, COCH3), 3.7 (s, 3H, OCH3),
6.3–8.0 (m, 7H, Ar-H), 8.4 (s, 1H, CH=N)
8 3362, 1746, 1631, 1601, 1539, 1302, 841, 534
2.4 (s, 3H, COCH3), 6.3–8.0 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
9 3000, 1739, 1682, 1604, 1535, 760, 519
2.4 (s, 3H, COCH3), 6.3–7.9 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N), 11.0 (s, 1H, COOH)
10 3451, 1710, 1673, 1605, 1388, 823, 506
2.4 (s, 3H, COCH3), 6.3–8.0 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
11 3348, 1700, 1702, 1570, 1340, 1268, 1050, 846
2.4 (s, 3H, COCH3), 3.7 (s, 3H, OCH3),
6.7–8.7 (m, 7H, Ar-H), 8.4 (s, 1H, CH=N)
12 3253, 1689, 1670, 1605, 1573, 1333, 820, 710
2.4 (s, 3H, COCH3), 6.4–8.7 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
13 3364, 1747, 1633, 1601, 1539, 1302, 845
2.4 (s, 3H, COCH3), 6.7–8.7 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
14 3000, 1710, 1684, 1607, 1564, 1332, 762
2.4 (s, 3H, COCH3), 6.7–8.7 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N), 11.0 (s, 1H, COOH)
15 3453, 1711, 1672, 1608, 1568, 1390, 1351, 825
2.4 (s, 3H, COCH3), 6.4–8.7 (m, 7H, Ar-H),
8.4 (s, 1H, CH=N)
Anticonvulsant screening
All the compounds were screened for anticonvulsant properties adopting the anti-
convulsant drug development (ADD) program protocol (17, 18). The mice used were
Carworth Farms No. 1, weighing from 19 to 25.5 g, either sex and 22–33 days old. Ac-
commodation conditions were maintained at 20 °C and the number of animals used was
1, 3, 5 and 8 in different experiments. Methyl cellulose was used for dissolving the rset
compounds in ScMet and Rotorod Test, while polyethylene glycol was used for MES.
The control experiments were performed with solvents alone. Three animals were used
in the control test. The compounds were administered intraperitoneally (0.01 mL g–1 body
mass) to mice, at doses of 30, 100 and 300 mg kg–1 to 1 to 4 mice. The activities of the
compounds in maximum electroshock (MES) and subcutaneous metrazole (ScMet) test
along with their neurotoxicity are presented in Table III.
Electroshock method. – Maximal seizures were induced by the application of electrical
current to the brain via corneal electrodes. The stimulus parameters for mice were 50
mA in a pulse of 60 Hz for 200 ms. The mice were given the test drug dissolved in poly-
ethylene glycol. Abolition of the hind limb tonic extensor spasm was recorded as a mea-
sure of anticonvulsant activity.
Subcutaneous metrazole seizure pattern test. – A metrazole dose of 85 mg kg–1 adminis-
tered subcutaneously to mice causes seizures in more than 97% of the animals. This is
called the convulsive dose 97 (CD97). The test was carried out by giving the metrazole
injection approximately 10 minutes before the anticipated time of the peak anticonvul-
sant drug action. The animals were observed during the following 4 hours for the occur-
rence of seizures. A threshold convulsion is defined as one episode of clonic spasms which
persists for at least 5 seconds. Absence of even a threshold convulsion during the period
of observation is taken as the endpoint in this test.
Rotorod test. – The mice were trained to stand on an accelerating rotorod rotating at
10 rev min–1. The rod diameter was 3.2 cm. Trained animals were given the test com-
pounds intraperitoneally at doses of 30, 100 and 300 mg kg–1 in methyl cellulose after 30
minutes and up to 24 hours. The mice were placed on the rotorod to measure the effect
of the drug on their motor performance. The dose at which animals fell off the rotorod
was determined.
The compounds were also screened at an oral dose of 30 mg kg–1 and the MES ac-
tivity was noted at different time intervals up to 4 hours.
Some compounds with OCH3/Cl substituent in phenyl, N-COCH3 and a substituent
Br/NO2 at the 5th position in the isatin moiety (compounds 6, 7, 11 and 12) and the com-
pound with fluoro substituent in the phenyl ring, N-COCH3 and a substituent Br at the
5th position in the isatin structure (compound 10) were screened at 6 Hz shock in mice at
a dose of 100 mg kg–1 up to 4 hours. The compounds were dissolved in methyl cellulose,
introduced via the i.p. route and the mice were given a current shock of 32 mA.
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RESULTS AND DISCUSSION
The results of anticonvulsant screening are given in Table III. The two primary
screens MES and ScMet were performed in mice at doses of 30, 100, 300 mg kg–1 (intra-
peritoneally). As compared to isatin, the 5-Br, N-CH3 isatin derivatives 2, 3, 4 with Cl,
NO2, COOH groups, respectively, in the phenyl ring, require a lower dose in MES while
the 5-Br, N-COCH3 isatin derivatives 9, 10 with F, COOH groups, respectively, in the
phenyl ring and 5-NO2, N-COCH3 isatin derivative 12 with NO2 group in the phenyl
ring showed activity in ScMet. In general, compounds with N-CH3 were active in the
MES test whereas those having N-COCH3 group showed activity in the ScMet test. The
N-methyl-5-bromo-3-(p-nitrophenylimino) isatin 3 and N-acetyl-5-bromo-3-(p-chloro-
phenylimino) isatin 10 have shown activity at a dose of 100 mg kg–1 in MES and ScMet,
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Table III. Anticonvulsant and neurotoxicity screening of isatin Schiff bases
Compd.
No.
Concentration (mg kg–1 body mass)a
MESa,b ScMeta,b Neurotoxicitya,b LD50 (mg kg–1)
1 – – 30 (25 %) 27
2 300 (100%) 300 (20%) – > 600
3 100 (33.3%) – 100 (50%) 100
4 300 (100%) – 300 (50%) > 300
5 – – 300 (50%) > 300
6 – – – > 300
7 – – 30 (25%) 27
8 – – 300 (25%) > 300
9 – 300 (60%) 100 (12.5%) 200
10 – 100 (20%) – > 300
11 – – – > 300
12 – 300 (80%) – 27
13 – – 100 (25%) 150
14 – – 30 (50%) 42
15 – – 30 (50%) 28
Isatin 400 (100%) – – > 400
Phenytoin 30 (100%) – 100 170  13
Carbamazepine 30 (100%) 100 (100%) 100 350
Valproic acid – 300 (100%) – > 1000
MES – maximal electroshock seizure, ScMet – subcutaneous metrazole seizure
– No activity.
a The two primary screens of MES, ScMet and toxicity were performed by intraperitoneal injection in mice at do-
ses of 30, 100, 300 mg kg–1.
b Values in parentheses in the MES and ScMet tests indicate the number of animals protected against the number of
animals tested and in the neurotoxicity test they indicate the number of animals exhibiting toxicity against the
number of animals tested. No protection of the solvent in control experiments was observed.
respectively. Compound 2 with bromo substituent in the isatin ring and chloro substi-
tuent in the phenyl ring showed activity both in MES and ScMet tests and no toxicity at
the stipulated doses. In 6 Hz excitation, the N-acetyl-5-nitro-3-(p-chlorophenylimino)
isatin 12 protected mice (25%) at a dose of 100 mg kg–1 after 15 minutes of drug adminis-
tration. In the oral test, N-methyl-5-bromo-3-(p-carboxyphenyl imino) isatin 4 showed
25% activity after half an hour at the dose of 30 mg kg–1 and N-acetyl-5-nitro-3-(p-ni-
trophenylimino) isatin 13 showed 25% activity after 2 hours at the dose of 50 mg kg–1.
N-methyl-5-bromo-3-(p-nitrophenylimino) isatin (3) showed activity in MES (100 mg kg–1
with 33.3% protection) as well as N-methyl-5-bromo-3-(p-aminophenylimino) isatin (4)
(300 mg kg–1 with 100% protection). N-methyl-5-bromo-3-(p-bromophenylimino) isatin
(2) showed activity both in MES (300 mg kg–1 with 100% protection) and ScMet (300 mg
kg–1 with 20% protection). The reference compound, valproic acid, was active only in
ScMet (300 mg kg–1 with 100% protection) whereas phenytoin was active in MES only.
Another reference compound, carbamazepine, was however active both in MES (30 mg
kg–1 with 100% protection) and in ScMet (100 mg kg–1 with 100% protection). It is worth-
wile to mention that the compound 2, being active both MES and ScMet, had LD50 > 600
mg kg–1 as compared to carbamazepine with the LD50 of 350 mg kg–1. Thus, compound
2 could be chosen as a lead compound for further modification aimed at improving the
anticonvulsant activity.
CONCLUSIONS
Compound 2 with bromo substituent in the isatin ring and chloro substituent in the
phenyl ring exhibited a broad-spectrum activity with no neurotoxicity at the stipulated
dose and can hence be chosen as a prototype for the development of new anticonvulsants.
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S A @ E T A K
Antikonvulzivno djelovanje Schiffovih baza – derivata isatina
MANJUSHA VERMA, SURENDRA NATH PANDEYA, KRISHNA NAND SINGH i JAMES P. STABLES
Schiffove baze N-metil i N-acetil derivata izatina s razli~itim aromatskim aminima
sintetizirane su i ispitane na sposobnost suzbijanja konvulzija uzrokovanih elektro{okom
(MES) i subkutanom primjenom metrazola (ScMet). N-metil-5-bromo-3-(p-klorofenilimi-
no) izatin 2 pokazao je nisku neurotoksi~nost i ja~e antikonvulzivno djelovanje nego
standardni antikonvulzivi fenitoin, karbamazepin i valproi~na kiselina. Zbog toga se
spoj 2 mo`e smatrati prototipom za razvoj novih antikonvulziva.
Klju~ne rije~i: Schiffova baza, izatin, antikonvulziv
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